Sumant Kulkarni, an analyst from Canaccord Genuity, maintained the Buy rating on Voyager Therapeutics. The associated price target remains the same with $12.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sumant Kulkarni has given his Buy rating due to a combination of factors related to Voyager Therapeutics’ strategic positioning and promising pipeline. The company’s focus on Alzheimer’s disease with four wholly-owned programs, including innovative gene therapies, highlights its commitment to addressing significant unmet medical needs. The utilization of proprietary TRACER capsid technology, which has garnered external partnerships, further validates the potential of their approach.
Additionally, Voyager Therapeutics has extended its financial runway into 2028, allowing it to navigate through upcoming clinical data milestones. The anticipation of internal and external catalysts, such as data from their anti-tau programs and partnerships, positions the company as undervalued in the current market. These elements collectively contribute to the positive outlook and Buy rating assigned by Sumant Kulkarni.
According to TipRanks, Kulkarni is a 4-star analyst with an average return of 4.3% and a 41.74% success rate. Kulkarni covers the Healthcare sector, focusing on stocks such as ACADIA Pharmaceuticals, ATAI Life Sciences, and COMPASS Pathways.
In another report released on August 11, H.C. Wainwright also reiterated a Buy rating on the stock with a $30.00 price target.